Megesterol: Difference between revisions
Varun Kumar (talk | contribs) No edit summary |
m (Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +)) |
||
Line 17: | Line 17: | ||
[[Category:Oncology]] | [[Category:Oncology]] | ||
{{WH}} | {{WH}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} |
Latest revision as of 17:17, 9 August 2012
WikiDoc Resources for Megesterol |
Articles |
---|
Most recent articles on Megesterol |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Megesterol at Clinical Trials.gov Clinical Trials on Megesterol at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Megesterol
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Megesterol Discussion groups on Megesterol Patient Handouts on Megesterol Directions to Hospitals Treating Megesterol Risk calculators and risk factors for Megesterol
|
Healthcare Provider Resources |
Causes & Risk Factors for Megesterol |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Megestrol is an appetite enhancing drug used to aid chemotherapy and HIV/AIDS patients gain mass. Little is known about the drug's chemical interactions. Doses Ranges from 80 mg po tid, 30 minutes before meals, to 800 mg po qd. Side effects may include diarrhea, rash, impotence, males may have some feminizing effects such as gynecomastia (breast development). It is a category X FDA drug, which means cannot be used in pregnancy as it crosses the placenta and malignantly affects the fetus.
References
2) http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=15064933&dopt=Abstract